Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 6/20 | 0.64 |
| ▸ | PPARG | P37231 | 5/20 | 0.55 |
| ▸ | PPARA | Q07869 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10219497 | 0.93 | PPARD (0.55) | PPARDPPARGPPARACYP3A4RAB9A | |
| SCHEMBL14143860 | 0.91 | PPARD (0.66) | PPARDPPARGPPARACYP3A4RAB9A | |
| SCHEMBL10219494 | 0.89 | PPARD (0.52) | PPARDPPARGPPARACYP3A4RAB9A | |
| SCHEMBL14144161 | 0.87 | PPARD (0.64) | PPARDPPARGPPARACYP3A4RAB9A | |
| SCHEMBL10220344 | 0.86 | PPARD (0.73) | PPARDPPARGPPARACYP3A4RAB9A | |
| SCHEMBL10220045 | 0.84 | PPARD (0.65) | PPARDPPARGPPARACYP3A4RAB9A | |
| SCHEMBL10219493 | 0.83 | PPARD (0.52) | PPARDPPARGPPARARAB9ANPC1 | |
| SCHEMBL334628 | 0.82 | PPARD (0.57) | PPARDPPARGPPARARAB9ANPC1 | |
| SCHEMBL27748074 | 0.81 | NPC1 (0.54) | PPARDPPARGPPARACYP3A4RAB9A | |
| SCHEMBL334014 | 0.81 | RAB9A (0.54) | PPARDPPARGRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296914-B | Derivatives with PPAR agonist activity | SHIONOGI & CO | 2012-07-18 | — | — | CN | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.